Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK127 in advanced solid tumors
NCT05393063Phase 1Unknown
- Sponsor
- Akeso, Inc.
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of AK127 in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Number of participants with adverse events (AEs) and Number of participants with a Dose Limiting Toxicity. Status: unknown.
02
Drugs
AK127
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05393063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393063.